Gena Wang
Stock Analyst at Barclays
(3.14)
# 1,183
Out of 5,124 analysts
239
Total ratings
43.59%
Success rate
1.74%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Gena Wang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CYTK Cytokinetics | Maintains: Overweight | $82 → $87 | $63.54 | +36.92% | 5 | Dec 22, 2025 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Overweight | $81 → $50 | $23.00 | +117.39% | 7 | Nov 24, 2025 | |
| LEGN Legend Biotech | Maintains: Overweight | $94 → $90 | $21.74 | +313.98% | 7 | Nov 13, 2025 | |
| FDMT 4D Molecular Therapeutics | Maintains: Overweight | $38 → $33 | $7.50 | +340.00% | 3 | Nov 11, 2025 | |
| MRNA Moderna | Maintains: Equal-Weight | $31 → $25 | $29.49 | -15.23% | 11 | Nov 7, 2025 | |
| NTLA Intellia Therapeutics | Maintains: Overweight | $24 → $14 | $8.99 | +55.73% | 9 | Nov 7, 2025 | |
| SGMO Sangamo Therapeutics | Downgrades: Equal-Weight | $5 → $1 | $0.42 | +138.10% | 5 | Nov 7, 2025 | |
| PTCT PTC Therapeutics | Maintains: Equal-Weight | $46 → $68 | $75.96 | -10.48% | 17 | Nov 6, 2025 | |
| SRPT Sarepta Therapeutics | Maintains: Equal-Weight | $22 → $20 | $21.52 | -7.06% | 16 | Nov 5, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Equal-Weight | $408 → $414 | $453.36 | -8.68% | 18 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $10 → $9 | $5.64 | +59.57% | 8 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $11 → $9 | $7.80 | +15.38% | 11 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $460 → $527 | $397.65 | +32.53% | 9 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $80 → $95 | $79.11 | +20.09% | 14 | Oct 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $86 → $80 | $59.43 | +34.61% | 16 | Oct 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $4 → $8 | $4.82 | +65.98% | 5 | Oct 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $7 → $17 | $27.96 | -39.20% | 10 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $50 → $37 | $14.41 | +156.77% | 7 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $59 → $62 | $72.13 | -14.04% | 4 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $42 → $56 | $52.44 | +6.79% | 17 | Aug 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $25 → $21 | $27.72 | -24.24% | 10 | Aug 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $26 → $31 | $6.03 | +414.10% | 6 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $5 → $3 | $2.05 | +46.34% | 9 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $9 | $26.33 | -65.82% | 1 | Dec 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $16 → $25 | $6.13 | +307.83% | 5 | Nov 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $32 → $18 | $7.95 | +126.42% | 2 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $21 → $9 | $5.95 | +51.26% | 6 | Aug 9, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $275 | $5.27 | +5,118.22% | 1 | Jan 6, 2017 |
Cytokinetics
Dec 22, 2025
Maintains: Overweight
Price Target: $82 → $87
Current: $63.54
Upside: +36.92%
Ultragenyx Pharmaceutical
Nov 24, 2025
Maintains: Overweight
Price Target: $81 → $50
Current: $23.00
Upside: +117.39%
Legend Biotech
Nov 13, 2025
Maintains: Overweight
Price Target: $94 → $90
Current: $21.74
Upside: +313.98%
4D Molecular Therapeutics
Nov 11, 2025
Maintains: Overweight
Price Target: $38 → $33
Current: $7.50
Upside: +340.00%
Moderna
Nov 7, 2025
Maintains: Equal-Weight
Price Target: $31 → $25
Current: $29.49
Upside: -15.23%
Intellia Therapeutics
Nov 7, 2025
Maintains: Overweight
Price Target: $24 → $14
Current: $8.99
Upside: +55.73%
Sangamo Therapeutics
Nov 7, 2025
Downgrades: Equal-Weight
Price Target: $5 → $1
Current: $0.42
Upside: +138.10%
PTC Therapeutics
Nov 6, 2025
Maintains: Equal-Weight
Price Target: $46 → $68
Current: $75.96
Upside: -10.48%
Sarepta Therapeutics
Nov 5, 2025
Maintains: Equal-Weight
Price Target: $22 → $20
Current: $21.52
Upside: -7.06%
Vertex Pharmaceuticals
Nov 4, 2025
Maintains: Equal-Weight
Price Target: $408 → $414
Current: $453.36
Upside: -8.68%
Nov 4, 2025
Maintains: Overweight
Price Target: $10 → $9
Current: $5.64
Upside: +59.57%
Nov 4, 2025
Maintains: Equal-Weight
Price Target: $11 → $9
Current: $7.80
Upside: +15.38%
Oct 31, 2025
Maintains: Overweight
Price Target: $460 → $527
Current: $397.65
Upside: +32.53%
Oct 30, 2025
Maintains: Overweight
Price Target: $80 → $95
Current: $79.11
Upside: +20.09%
Oct 28, 2025
Maintains: Overweight
Price Target: $86 → $80
Current: $59.43
Upside: +34.61%
Oct 17, 2025
Maintains: Overweight
Price Target: $4 → $8
Current: $4.82
Upside: +65.98%
Sep 25, 2025
Upgrades: Equal-Weight
Price Target: $7 → $17
Current: $27.96
Upside: -39.20%
Aug 8, 2025
Maintains: Overweight
Price Target: $50 → $37
Current: $14.41
Upside: +156.77%
Aug 8, 2025
Maintains: Overweight
Price Target: $59 → $62
Current: $72.13
Upside: -14.04%
Aug 6, 2025
Maintains: Equal-Weight
Price Target: $42 → $56
Current: $52.44
Upside: +6.79%
Aug 6, 2025
Maintains: Equal-Weight
Price Target: $25 → $21
Current: $27.72
Upside: -24.24%
Feb 28, 2025
Maintains: Overweight
Price Target: $26 → $31
Current: $6.03
Upside: +414.10%
Dec 13, 2024
Maintains: Equal-Weight
Price Target: $5 → $3
Current: $2.05
Upside: +46.34%
Dec 22, 2022
Maintains: Equal-Weight
Price Target: $7 → $9
Current: $26.33
Upside: -65.82%
Nov 2, 2022
Upgrades: Equal-Weight
Price Target: $16 → $25
Current: $6.13
Upside: +307.83%
May 13, 2022
Maintains: Overweight
Price Target: $32 → $18
Current: $7.95
Upside: +126.42%
Aug 9, 2019
Maintains: Underweight
Price Target: $21 → $9
Current: $5.95
Upside: +51.26%
Jan 6, 2017
Initiates: Buy
Price Target: $275
Current: $5.27
Upside: +5,118.22%